文献速递临床试验与 GCP

使用Glubran 2®无引流腋窝淋巴结清扫术中控制血清肿的多中心、前瞻性、随机临床试验:GALA-ND研究(Glubran、腋窝淋巴结清扫、日间手术、无引流)

Seroma control in axillary lymphadenectomy with Glubran 2® without drain. Multicenter, prospective, randomized, clinical trial. GALA-ND study (Glubran, Axillary Lymphadenectomy, Ambulatory, No Drain).
PubMed 文献 · Trials · 2024-02-22

本研究为前瞻性、多中心、国际随机临床试验,纳入接受保乳手术及腋窝淋巴结清扫的乳腺癌患者,随机分为对照组(无密封剂淋巴结清扫)和干预组(使用Glubran 2®密封剂淋巴结清扫),两组均不放置引流。主要结局为有症状血清肿,次要结局包括血清肿体积、发病率、生活质量和淋巴水肿,随访至术后6-12个月。

要点

  • 无引流腋窝淋巴结清扫后症状性血清肿发生率为19%。
  • 研究旨在评估Glubran 2®密封剂在无引流条件下控制血清肿的效果。
  • 招募接受保乳手术和腋窝淋巴结清扫的乳腺癌患者,包括新辅助治疗者。

核心结论

  • 作者希望证明接受腋窝淋巴结清扫的患者可从无引流的腋窝密封剂中获益,减少腋窝不适并维持良好生活质量。
  • 评估腋窝体积、症状与相关风险因素的关系可能对乳腺癌术后血清肿控制有很大帮助。

研究设计与样本

  • 前瞻性、多中心、国际随机临床试验。
  • 接受保乳手术和腋窝淋巴结清扫的乳腺癌患者随机分为对照组(无密封剂淋巴结清扫)或干预组(使用Glubran 2®密封剂淋巴结清扫),两组均不放置引流。
  • 纳入接受新辅助治疗的患者。
  • 结局测量在基线、术后7天、14天、30天以及6-12个月进行。

主要发现

  • 无引流腋窝淋巴结清扫后症状性血清肿发生率为19%。

关键数值与推荐

  • 主要结局为有症状血清肿。
  • 次要结局为血清肿体积、发病率、生活质量和淋巴水肿。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Seroma after breast cancer surgery is a frequent entity; therefore, different products have been described in literature with the aim to reduce it. The most studied ones have been the sealants products, being tested with aspirative drains. Symptomatic seroma represents the 19% after axillary lymphadenectomy without drains. The aim of this study is to analyze the effect of a sealant in the seroma control after axillary lymphadenectomy without drains and identify the risk factors related to symptomatic seroma. METHODS: This is a prospective, multicenter, international, and randomized clinical trial. Patients undergoing conservative surgery and axillary lymphadenectomy for breast cancer will be randomized to control group (lymphadenectomy without sealant) or interventional group (lymphadenectomy with sealant Glubran 2®). In any of the study groups, drains are placed. Patients who received neoadjuvant treatment are included. Measurements of the study outcomes will take place at baseline; at 7, 14, and 30 days post-surgery; and at 6-12 months. The primary outcome is symptomatic seroma. Secondary outcomes are seroma volume, morbidity, quality of life, and lymphedema. DISCUSSION: Several studies compare the use of sealant products in axillary lymphadenectomy but generally with drains. We would like to demonstrate that patients who underwent axillary lymphadenectomy could benefit from an axillary sealant without drains and reduce axillary discomfort while maintaining a good quality of life. Assessing the relationship between axillary volume, symptoms, and related risk factors can be of great help in the control of seroma in patients who received breast cancer surgery. TRIAL REGISTRATION: ClinicalTrials.gov, NCT05280353. Registration date 02 August 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. López Gordo S, Ruiz-Edo N, Fernández-Planas MT, et al. Seroma control in axillary lymphadenectomy with Glubran 2® without drain. Multicenter, prospective, randomized, clinical trial. GALA-ND study (Glubran, Axillary Lymphadenectomy, Ambulatory, No Drain). Trials. 2024. PMID: 38388444. doi:10.1186/s13063-023-07840-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。